JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
REVIEW
Add like
Add dislike
Add to saved papers

Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome.

A regimen in which a GnRH agonist is used with estrogen-progestin replacement provides a significant potential advance in the treatment of PMS. Substantial evidence indicates that the pathophysiology of PMS is dependent on cyclic progesterone changes which, after a time delay, influence central neurotransmitter systems and peripheral tissues. Because of the myriad neurotransmitter changes induced by progesterone, the most comprehensive treatment of the complex array of symptoms in severe PMS may require pharmacologic agents that reduce circulating progesterone levels. The most effective agent in this regard in a GnRH analogue. Until recently, use of these analogues has been limited to short-term courses as a result of the deleterious effects of hypoestrogenism. Based on newer information, a regimen in which a GnRH agonist is used concomitantly with CEE and MPA replacement appears to ameliorate PMS symptoms substantially while providing a proven estrogen-progestin replacement therapy to protect against the side effects of hypoestrogenism. Before treatment, an accurate diagnosis must be made that rests on exclusion of concomitant psychiatric and/or medical diagnoses and prospective symptom recording. In addition, before use of the GnRH agonist and estrogen-progestin add-back treatment, consideration should be given to agents, such as fluoxetine and alprazolam, which target specific neurotransmitter alterations. Currently, the superiority of one agent over others has not been tested in controlled trials. Nonetheless, in patients who cannot tolerate or do not respond to fluoxetine and alprazolam, a GnRH agonist plus estrogen and progestin appears the indicated treatment of choice.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app